Last updated: 17 July 2019 at 12:38pm EST

Dr. Mai Hope Le M.D. Net Worth



Dr. Mai Hope Le M.D. biography

Dr. Mai Hope Le M.D. is the Consultant at OncoSec Medical Inc.



How old is Dr D?

Dr D is 45, he's been the Consultant of OncoSec Medical Inc since . There are 10 older and 1 younger executives at OncoSec Medical Inc. The oldest executive at OncoSec Medical Inc is Margaret Dalesandro, 73, who is the Independent Chairman of the Board.

What's Dr D's mailing address?

Mai's mailing address filed with the SEC is 9810 SUMMERS RIDGE ROAD, SUITE 110, SAN DIEGO, CA, 92121.

Insiders trading at OncoSec Medical Inc

Over the last 12 years, insiders at OncoSec Medical Inc have traded over $1,474,366 worth of OncoSec Medical Inc stock and bought 9,275,650 units worth $39,853,210 . The most active insiders traders include Grand Pharmaceutical & Heal..., Holdings, Inc. Alpha и Robert Ward. On average, OncoSec Medical Inc executives and independent directors trade stock every 62 days with the average trade being worth of $51,563. The most recent stock trade was executed by Robert J Del Aversano on 9 February 2023, trading 40 units of ONCS stock currently worth $55.



What does OncoSec Medical Inc do?

oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar



OncoSec Medical Inc executives and stock owners

OncoSec Medical Inc executives and other stock owners filed with the SEC include: